達安基因(002030.SZ):上半年擬計提各項資產減值準備合計約1.43億元
格隆匯 7 月 29日丨達安基因(002030.SZ)公佈,經過公司及下屬子公司對2020年半年度末可能存在減值跡象的資產進行全面清查,其中:對應收保理款綜合考慮包括貸款質量、借款人的財務狀況、還款能力和還款意向、抵押品的可變現價值、保證人的代償能力、借款人所屬的行業以及宏觀經濟、法律及監管環境等進行分類和計提減值損失。對公司的各類資產進行了全面檢查和減值測試後,2020年半年度公司及下屬子公司擬計提各項資產減值準備合計約1.43億元。
經公司測算,此次計提各項資產減值準備合計約1.43億元,考慮所得税及少數股東損益影響後,將減少公司2020上半年歸屬上市公司股東的淨利潤5702.18萬元,相應減少本報告期末歸屬於上市公司股東的所有者權益5702.18萬元。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.